BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38251559)

  • 1. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve.
    Mackie SL; Bhogal R
    Lancet Rheumatol; 2023 Dec; 5(12):e703-e705. PubMed ID: 38251559
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?].
    Samson M; Bonnotte B
    Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104
    [No Abstract]   [Full Text] [Related]  

  • 3. The long-term use of tocilizumab in giant cell arteritis.
    Coath FL; Mukhtyar C
    Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory giant cell arteritis on prednisone and tocilizumab: improvement with subsequent tuberculosis reactivation.
    Kherani I; Chin C; Kherani RB; Kherani F
    Can J Ophthalmol; 2019 Aug; 54(4):e192-e194. PubMed ID: 31358167
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
    Broner J; Arnaud E
    Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for giant cell arteritis: what is optimal?
    Kaymakci M; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):777-779. PubMed ID: 36995336
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits.
    Buttgereit F; Palmowski A; Esen I; Brouwer E
    Arthritis Rheumatol; 2023 Apr; 75(4):489-492. PubMed ID: 36468520
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of large-vessel giant cell arteritis despite tocilizumab treatment.
    Elfishawi M; Kaymakci M; Koster MJ; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):985-986. PubMed ID: 35930482
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
    Gordon LK; Sadun AA; Van Stavern G; Lee AG
    J Neuroophthalmol; 2022 Jun; 42(2):e535-e536. PubMed ID: 35594160
    [No Abstract]   [Full Text] [Related]  

  • 13. The Treatment of Giant Cell Arteritis in Different Clinical Settings.
    Pfeil A; Oelzner P; Hellmann P
    Front Immunol; 2018; 9():3129. PubMed ID: 30733723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of giant cell arteritis patients treated with tocilizumab in a single neuro-ophthalmology practice.
    Fong JW; Sharieff JA; Patel AD
    Can J Ophthalmol; 2023 Apr; 58(2):e61-e62. PubMed ID: 36126697
    [No Abstract]   [Full Text] [Related]  

  • 15. Trial of Tocilizumab in Giant-Cell Arteritis.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
    N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyalgia Rheumatica and Giant Cell Arteritis.
    Buttgereit F; Matteson EL; Dejaco C
    JAMA; 2020 Sep; 324(10):993-994. PubMed ID: 32897333
    [No Abstract]   [Full Text] [Related]  

  • 17. Giant cell arteritis: new concepts, treatments and the unmet need that remains.
    Coath F; Gillbert K; Griffiths B; Hall F; Kay L; Lanyon P; Luqmani R; Mackie SL; Mason JC; Mills J; Mollan S; Morgan AW; Mukhtyar C; Quick V; Watts R; Dasgupta B
    Rheumatology (Oxford); 2019 Jul; 58(7):1123-1125. PubMed ID: 30423174
    [No Abstract]   [Full Text] [Related]  

  • 18. Giant cell arteritis: An updated review of an old disease.
    Rinden T; Miller E; Nasr R
    Cleve Clin J Med; 2019 Jul; 86(7):465-472. PubMed ID: 31291180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab in Giant Cell Arteritis.
    Mariano VJ; Frishman WH
    Cardiol Rev; 2018; 26(6):321-330. PubMed ID: 29570475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.